Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade
- PMID: 30902885
- DOI: 10.1136/gutjnl-2019-318419
Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade
Abstract
Objective: In the tumour microenvironment, critical drivers of immune escape include the oncogenic activity of the tumour cell-intrinsic osteopontin (OPN), the expression of programmed death ligand 1 (PD-L1) and the expansion of tumour-associated macrophages (TAMs). We investigated the feasibility of targeting these pathways as a therapeutic option in hepatocellular carcinoma (HCC) mouse models.
Design: We analysed the number of tumour-infiltrating immune cells and the inflammatory immune profiles in chemically induced liver tumour isolated from wild-type and OPNknockout (KO) mice. In vitro cell cocultures were further conducted to investigate the crosstalk between TAMs and HCC cells mediated by OPN, colony stimulating factor-1 (CSF1) and CSF1 receptor (CSF1R). The in vivo efficacy of anti-PD-L1 and CSF1/CSF1R inhibition was evaluated in OPN overexpressing subcutaneous or orthotopic mouse model of HCC.
Results: The numbers of TAMs, as well as the expression levels of M2 macrophage markers and PD-L1 were significantly decreased, but the levels of cytokines produced by T-helper 1 (Th1) cells were upregulated in tumour tissues from OPN KO mice compared with that from the controls. In addition, we observed a positive association between the OPN and PD-L1 expression, and OPN expression and TAM infiltration in tumour tissues from patients with HCC. We further demonstrated that OPN facilitates chemotactic migration, and alternative activation of macrophages, and promotes the PD-L1 expression in HCC via activation of the CSF1-CSF1R pathway in macrophages. Combining anti-PD-L1 and CSF1R inhibition elicited potent antitumour activity and prolonged survival of OPNhigh tumour-bearing mice. Histological, flow cytometric and ELISA revealed increased CD8+ T cell infiltration, reduced TAMs and enhanced Th1/Th2 cytokine balance in multiple mouse models of HCC.
Conclusions: OPN/CSF1/CSF1R axis plays a critical role in the immunosuppressive nature of the HCC microenvironment. Blocking CSF1/CSF1R prevents TAM trafficking and thereby enhances the efficacy of immune checkpoint inhibitors for the treatment of HCC.
Keywords: anti-PD-L1; hepatocellular carcinoma; immune checkpoint blockade; tumor microenvironment.
© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: None declared.
Comment in
-
Hepatocellular carcinoma: killing one bird with two stones.Gut. 2019 Sep;68(9):1543-1544. doi: 10.1136/gutjnl-2019-318649. Epub 2019 May 10. Gut. 2019. PMID: 31076399 No abstract available.
-
Meta-analysis of the efficacy and safety of PD-1/PD-L1 inhibitors administered alone or in combination with anti-VEGF agents in advanced hepatocellular carcinoma.Gut. 2020 Oct;69(10):1904-1906. doi: 10.1136/gutjnl-2019-320116. Epub 2019 Dec 18. Gut. 2020. PMID: 31852768 No abstract available.
Similar articles
-
IL-1β-Induced Elevation of Solute Carrier Family 7 Member 11 Promotes Hepatocellular Carcinoma Metastasis Through Up-regulating Programmed Death Ligand 1 and Colony-Stimulating Factor 1.Hepatology. 2021 Dec;74(6):3174-3193. doi: 10.1002/hep.32062. Epub 2021 Aug 27. Hepatology. 2021. PMID: 34288020
-
Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma.Int J Mol Sci. 2021 Apr 29;22(9):4710. doi: 10.3390/ijms22094710. Int J Mol Sci. 2021. PMID: 33946835 Free PMC article.
-
Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma.Gut. 2017 Jan;66(1):157-167. doi: 10.1136/gutjnl-2015-310514. Epub 2015 Oct 9. Gut. 2017. PMID: 26452628
-
Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma.J Immunother Cancer. 2020 Apr;8(1):e000394. doi: 10.1136/jitc-2019-000394. J Immunother Cancer. 2020. PMID: 32303615 Free PMC article.
-
Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives.Clin Transl Oncol. 2019 Jun;21(6):702-712. doi: 10.1007/s12094-018-1975-4. Epub 2018 Nov 1. Clin Transl Oncol. 2019. PMID: 30387047 Review.
Cited by
-
A novel panel based on immune infiltration and tumor mutational burden for prognostic prediction in hepatocellular carcinoma.Aging (Albany NY). 2021 Mar 10;13(6):8563-8587. doi: 10.18632/aging.202670. Epub 2021 Mar 10. Aging (Albany NY). 2021. PMID: 33714200 Free PMC article.
-
Mitoribosome Defect in Hepatocellular Carcinoma Promotes an Aggressive Phenotype with Suppressed Immune Reaction.iScience. 2020 Jun 26;23(6):101247. doi: 10.1016/j.isci.2020.101247. Epub 2020 Jun 7. iScience. 2020. PMID: 32629612 Free PMC article.
-
Osteopontin Takes Center Stage in Chronic Liver Disease.Hepatology. 2021 Apr;73(4):1594-1608. doi: 10.1002/hep.31582. Hepatology. 2021. PMID: 32986864 Free PMC article. Review.
-
Molecular Bases of Drug Resistance in Hepatocellular Carcinoma.Cancers (Basel). 2020 Jun 23;12(6):1663. doi: 10.3390/cancers12061663. Cancers (Basel). 2020. PMID: 32585893 Free PMC article. Review.
-
MicroRNAs in Hepatocellular Carcinoma Pathogenesis: Insights into Mechanisms and Therapeutic Opportunities.Int J Mol Sci. 2024 Aug 29;25(17):9393. doi: 10.3390/ijms25179393. Int J Mol Sci. 2024. PMID: 39273339 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous